GeoVax Labs (NASDAQ:GOVX) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of GeoVax Labs (NASDAQ:GOVX) in a report released on Monday, Benzinga reports. The firm currently has a $8.00 target price on the stock.

GOVX has been the topic of several other research reports. Roth Mkm began coverage on shares of GeoVax Labs in a research note on Tuesday, July 16th. They set a buy rating and a $20.00 price objective on the stock. Roth Capital upgraded shares of GeoVax Labs to a strong-buy rating in a research note on Tuesday, July 16th. Finally, EF Hutton Acquisition Co. I upgraded shares of GeoVax Labs to a strong-buy rating in a research report on Tuesday, July 23rd.

GeoVax Labs Trading Up 30.0 %

GOVX opened at $3.25 on Monday. GeoVax Labs has a fifty-two week low of $1.09 and a fifty-two week high of $9.75. The company’s 50-day moving average price is $2.36 and its 200 day moving average price is $2.14.

GeoVax Labs (NASDAQ:GOVX) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($1.99) earnings per share for the quarter, topping the consensus estimate of ($2.57) by $0.58. The business had revenue of $0.30 million for the quarter. During the same quarter last year, the business posted ($3.30) EPS. Equities analysts expect that GeoVax Labs will post -7.41 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in GeoVax Labs stock. Armistice Capital LLC bought a new position in GeoVax Labs, Inc. (NASDAQ:GOVX) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,626,516 shares of the company’s stock, valued at approximately $587,000. Armistice Capital LLC owned about 91.38% of GeoVax Labs at the end of the most recent quarter. Hedge funds and other institutional investors own 6.09% of the company’s stock.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.